Cyclopharm Limited

Equities

CYC

AU000000CYC5

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. 02:10:22 2024-06-14 am EDT 5-day change 1st Jan Change
1.54 AUD -0.65% Intraday chart for Cyclopharm Limited -1.28% -20.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Cyclopharm Raises AU$20 Million Share Placement for Technegas Commercialization; Shares Down 16% MT
Cyclopharm to Raise AU$20 Million via Placement, AU$2 Million via Share Purchase Plan MT
Cyclopharm's Technegas Device Carries Out Imaging of First US Patients MT
Cyclopharm Limited(ASX:CYC) added to S&P/ASX All Ordinaries Index CI
Cyclopharm Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Cyclopharm Limited Appoints John Wigglesworth to its Board as Non- Executive Director CI
Cyclopharm Appoints CFO; Shares Rise 3% MT
Cyclopharm Signs First US Deal for Inhalable Imaging Product MT
Argenica Therapeutics Appoints Nonexecutive Chair MT
Cyclopharm Advances Rollout of Imaging Drug in the US MT
Cyclopharm Says U.S. SNMMI Confirms FDA Nod for Technegas MT
Cyclopharm Secures US FDA Clearance for Inhalable Imaging Product; Shares Rise 5% MT
Cyclopharm Limited Declares Unfranked Interim Dividend for the Six Months Ended June 30, 2023, Payable on 11 September 2023 CI
Cyclopharm Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
US FDA Completes Site Inspection for Cyclopharm’s Technegas Facility MT
Australian Shares Retreat Ahead of Federal Budget MT
Cyclopharm Secures US FDA Inspection Date for Imaging Drug Production Facility; Shares Rise 4% MT
US FDA Confirms Receipt of Cyclopharm's Response Submission for Inhalable Imaging Agent MT
Cyclopharm Takes Over Denmark-based DuPharma ApS MT
Cyclopharm Limited acquired Dupharma Aps. CI
Cyclopharm Limited announced that it expects to receive AUD 0.218 million in funding CI
Cyclopharm Files Formal Reply to US FDA for Inhalable Imaging Agent MT
Cyclopharm Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Cyclopharm Limited Announces Dividend for A Period of Six Months Ended December 31, 2022, Payable on April 4 2023 CI
Cyclopharm Receives $1.1 Million R&D Tax Rebate MT
Chart Cyclopharm Limited
More charts
Cyclopharm Limited is an Australia-based radiopharmaceutical company. The Company's principal activity is engaged in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development and distribution of third-party products to the diagnostic imaging sector. Its segments include Technegas and Molecular Imaging. The Technegas segment is a supplier of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment produces radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders and cardiac disease. The Company uses Technegas technology, which is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using driedTechnetium-99m in a carbon crucible. The Company distributes its products in approximately 65 countries.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.023 USD
Average target price
2.884 USD
Spread / Average Target
+182.00%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. CYC Stock
  4. News Cyclopharm Limited
  5. Cyclopharm to Raise AU$20 Million via Placement, AU$2 Million via Share Purchase Plan